Eton Pharmaceuticals Reports Fourth Quarter 2024 Financial Results
Management to Hold Investor Day Conference Call Today at 10:00am ETReported record product revenue of $11.6 million in Q4 2024, an increase of ...
Eton Pharmaceuticals Announces Positive Pivotal Clinical Study Results for Product Candidate ET-600
Company’s patented desmopressin oral solution successfully passed pivotal bioequivalence study -- Company expects to submit New Drug ...
Morningstar5d
Eton Pharmaceuticals Announces Positive Pivotal Clinical Study Results for Product Candidate ET-600
The Company currently has seven commercial rare disease products: INCRELEX®, ALKINDI SPRINKLE®, GALZIN®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has four ...
Eton Pharmaceuticals (ETON) to Release Earnings on Thursday
Eton Pharmaceuticals (NASDAQ:ETON – Get Free Report) will likely be issuing its quarterly earnings data before the market opens on Thursday, March 13th. Analysts expect the company to announce ...
The Bakersfield Californian15d
Eton Pharmaceuticals to Host Virtual Investor Day and Release Fourth Quarter Earnings Results ...
Alkindi Sprinkle® and ET-400, and the associated market landscape. In addition, the company will highlight recent developments within its pipeline of attractive rare disease product candidates.
Nasdaq4d
Eton Pharmaceuticals Announces Successful Bioequivalence Study Results for ET-600, Plans NDA Submission in April 2025
The Company currently has seven commercial rare disease products: INCRELEX®, ALKINDI SPRINKLE®, GALZIN®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has four ...
The Globe and Mail12d
Eton Pharmaceuticals Announces Extension of PDUFA Goal Date for ET-400
The Company currently has seven commercial rare disease products: INCRELEX®, ALKINDI SPRINKLE®, GALZIN®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has four ...